Hannah Clarke

Interim results reveal promising efficacy and safety of sacituzumab govitecan and pembrolizumab for muscle-invasive bladder cancer, enabling bladder preservation.

An expanded access program evaluating cretostimogene grenadenorepvec was highlighted during the 25th Annual Meeting of the Society of Urologic Oncology.

A study found that enfortumab vedotin with pembrolizumab significantly improves survival and maintains quality-of-life compared with chemotherapy for locally advanced or metastatic urothelial cancer.

Results from the AURA trial show the survival benefits of cisplatin-based chemotherapy in combination with avelumab.

Adding niraparib to abiraterone acetate and prednisone was associated with an overall survival benefit compared with AAP alone in patients with BRCA1/2-mutated metastatic castration-resistant prostate cancer.

Adding 177Lu-PSMA-617 to enzalutamide improved prostate-specific antigen progression-free survival in patients with metastatic castration-resistant prostate cancer.

TALAPRO-2 is the first phase 3 study to evaluate talazoparib plus enzalutamide as a first-line treatment in patients with metastatic castration resistant prostate cancer.